Visual acuity improvement after aflibercept injection maintained over 3 years

Posted on

Long-term aflibercept injection achieve visual improvement and reduced the thickness of the retina and choroid in patients with neovascular age-related macular degeneration (nAMD), according to a study published in BMC Ophthalmology.

In this prospective study, 49 patients (50 eyes) with treatment-naïve nAMD received intravitreal aflibercept injection every 2 months for the first year before switching to a treat-and-extend approach in the subsequent 2 years.

Of the 28 patients (29 eyes) who completed the 36 months follow-up, 15 eyes had typical AMD and 14 had polypoidal choroidal vasculopathy.

Over the course of 3 years, the number of ntravitreal aflibercept injections performed was 17.2±3.1 (mean±standard deviation). At baseline, the mean logMAR was 0.42, and improved to 0.19 at 12months and 0.26 at 36months. Central retinal thickness was 329±120μm, 151±38μm, and 143±61μm at baseline, 12 months, and 36 months respectively. The mean subfoveal choroidal thickness (SFCT) was 288±97μm at baseline, 243±82μm at 12months, and 208±63μm at 36months. No difference was noted between typical AMD and polypoidal choroidal vasculopathy.


Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration. BMC Ophthalmol. 2020;20:276. https://doi.org/10.1186/s12886-020-01542-6



Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021